Will Mounjaro's price go up, and how should that affect your decision?

Why Mounjaro's price rose, and what could push it further

The September 2025 price increase was driven by Eli Lilly revising its UK wholesale list price, not by individual pharmacies acting independently. Private providers largely followed suit because the medicine's cost to them went up. That single change turned a roughly £120-per-pen market into one where comparable doses are now typically priced between £149 and £375 a month depending on dose, provider, and what's included. Those figures come from widely reported market coverage and are hedged as such, real quotes vary.

Several factors could move prices again. NHS commissioning is expanding: the phased NHS rollout of tirzepatide creates a larger purchasing base, which could influence how Lilly prices to the market long-term. Equally, new manufacturing capacity, biosimilar development timelines (some years away), and currency effects all play a role. No credible source can guarantee a direction, and if you want a closer look at whether Mounjaro is likely to go up in price further, that page works through the key variables analysts are watching. If you want a closer look at the specific trajectory analysts are watching, our breakdown of the tirzepatide price increase covers the background in detail.

The practical upshot: prices are not going back to pre-September 2025 levels in the near term. Planning your budget around current market rates is more realistic than hoping for a reversal.

What headline prices often leave out, and why comparisons mislead

A quoted monthly price for Mounjaro means very little without knowing what it covers. Some providers price the pen alone and add separate consultation fees, prescription charges, delivery costs, or dose-review fees each time your treatment changes. A low headline figure can become considerably more expensive once those elements are counted. This isn't unique to weight-loss treatment, it's a pattern across private healthcare generally.

The things worth checking for are: whether clinical re-review before each repeat order is included, whether aftercare support has a separate cost, and whether delivery is genuinely free at all doses. You can usually find the answers in fewer than a minute by reading a provider's pricing page end-to-end before entering any personal details. Worth doing.

For a fuller picture of what drives the monthly cost at different doses, our Mounjaro pricing page sets out what to look for. And if you're curious how much the market expects prices to reach, this page addresses the upper-range estimates with the same caveats applied.

How nume prices treatment, and why we don't lead on being cheap

We charge one transparent price that includes the consultation, prescription, medicine, and free next-working-day delivery by DPD. Priority prescriber support seven days a week is part of that too. There are no repeat fees, no subscription to manage, and no separate delivery charge that appears at checkout. Every repeat order is clinically re-reviewed by a named prescriber before it goes out, not rubber-stamped.

We are not the cheapest option on the market, and that is deliberate. A lower price usually means something is unbundled, a clinical step is thinner, or the supply chain is worth scrutinising. Our medicines come through the licensed UK supply chain, with Eli Lilly as the authorised manufacturer. Our pharmacy is GPhC-registered, you can verify our registration on the GPhC register in seconds. That infrastructure has a cost, and we think it's one worth paying.

You can see current treatment pricing on our treatments page, where everything is shown upfront. No hidden figures revealed later.

Why 'cheapest' is the wrong test for a prescription medicine

Mounjaro cannot legally be supplied without a prescription following proper clinical assessment. That requirement exists because tirzepatide has a real side-effect profile (including GI effects and, as flagged in an MHRA Drug Safety Update, the importance of recognising symptoms that might indicate pancreatitis) and because not everyone is a suitable candidate. The MHRA has confirmed enforcement action against fake weight-loss pens sold online, some containing insulin rather than tirzepatide, with hospitalisations resulting. Prices dramatically below the current market rate are a warning sign, not a bargain.

The right questions aren't about who charges least. They're about whether a prescriber who knows your medical history has approved your treatment, whether the medicine is genuine and stored correctly, and whether someone qualified is available if something doesn't feel right. Our clinical team, led by GPhC-registered prescribers, reviews every consultation personally, the same day you submit it. That's the standard you should expect from any provider, regardless of price.

If you're weighing up the full picture on Mounjaro before making a decision, our main pillar page covers how the medicine works, what the evidence says, and what to discuss with a prescriber. Or if you're ready to take the next step, start your free consultation and a prescriber will review your answers the same day.